secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001558370-24-012133
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q2 2024: revenue $13.5M, net loss $2.2M; PRX-115 Phase I topline expected Q3
--------------------------------------------------------------------------------

- Total Q2 2024 revenue $13.5M vs $35.1M in Q2 2023; net loss $2.2M ($0.03/sh) vs net income $19.3M ($0.29/sh).
- Product revenue from goods $13.3M (-12% YoY); license & R&D revenue $0.2M (vs $20.0M milestone from Chiesi in Q2 2023).
- PRX-115 (uncontrolled gout) Phase I: positive topline from first 7 cohorts; 8th cohort dosed, full results expected Q3 2024.
- Cash, cash equivalents and short-term bank deposits $45.0M at June 30, 2024; post-quarter collected $4.6M from Pfizer, $2.3M from Brazil.
- R&D expenses decreased 33% to $3.0M due to completion of Fabry clinical program and Elfabrio regulatory processes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024012133/0001558370-24-012133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024012133/plx-20240814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer